| Early Adolescent Emergence of Reversal Learning Impairments in Isolation-Reared Rats SB Powell, A Khan, JW Young, CN Scott, MR Buell, S Caldwell, E Tsan, ... Developmental Neuroscience 37 (3), 253-262, 2015 | 34 | 2015 |
| Time course, outcome and management of adverse drug reactions associated with metformin from patient’s perspective: a prospective, observational cohort study in the Netherlands L de Jong, L Härmark, E van Puijenbroek European journal of clinical pharmacology 72, 615-622, 2016 | 30 | 2016 |
| Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis: a clinical pharmacological perspective on a surgical procedure. LAW de Jong, FMK Elekonawo, PR de Reuver, AJA Bremers, JHW de Wilt, ... British Journal of Clinical Pharmacology, 2018 | 26 | 2018 |
| Adolescent GBR12909 exposure induces oxidative stress, disrupts parvalbumin-positive interneurons, and leads to hyperactivity and impulsivity in adult mice A Khan, LAW De Jong, ME Kamenski, KK Higa, JD Lucero, JW Young, ... Neuroscience 345, 166-175, 2017 | 18 | 2017 |
| Consecutive antibiotic use in the outpatient setting: an extensive, longitudinal descriptive analysis of antibiotic dispensing data in the Netherlands LAW De Jong, PD van der Linden, MMB Roukens, EMW van de Garde, ... BMC Infectious Diseases 19, 1-8, 2019 | 17 | 2019 |
| Muscle rupture associated with statin use C Ekhart, L de Jong, L Gross‐Martirosyan, F van Hunsel British journal of clinical pharmacology 82 (2), 473-477, 2016 | 13 | 2016 |
| Pressurized intraperitoneal aerosol chemotherapy: The road from promise to proof LAW de Jong, NP van Erp, L Bijelic Clinical Cancer Research 27 (7), 1830-1832, 2021 | 9 | 2021 |
| Effect of intraperitoneal chemotherapy concentration on morbidity and survival FMK Elekonawo, WJ Eden, WY Plas, RSG Ewalds, LAW Jong, ... BJS open 4 (2), 293-300, 2020 | 9 | 2020 |
| Wide variation in tissue, systemic, and drain fluid exposure after oxaliplatin-based HIPEC: results of the GUTOX study LAW de Jong, FMK Elekonawo, M Lambert, JM de Gooyer, HMW Verheul, ... Cancer Chemotherapy and Pharmacology 86, 141-150, 2020 | 5 | 2020 |
| High-dose short-term osimertinib treatment is effective in patient-derived metastatic colorectal cancer organoids KK Iyer, D Poel, A Miggelenbrink, W Kerkhof, J Janssen, L Bakkerus, ... BJC Reports 2 (1), 29, 2024 | 2 | 2024 |
| (Es) omeprazole and discoloration of regurgitated gastric contents in infants: worrying for care-takers and a sign of a reduced bioavailability F van Hunsel, L de Jong, T de Vries The Journal of Pediatric Pharmacology and Therapeutics 21 (3), 260-262, 2016 | 2 | 2016 |
| Cerebrospinal Fluid Concentration of the RET Inhibitor Pralsetinib: A Case Report LAW De Jong, RW Sparidans, MM van den Heuvel Case Reports in Oncology 16 (1), 1579-1585, 2023 | 1 | 2023 |
| Effect of aprepitant on etoposide pharmacokinetics in patients with testicular cancer: a pharmacokinetic study to determine the absence of a clinically relevant interaction J Strik, LAW de Jong, J Sijm, IME Desar, NP van Erp Clinical Pharmacology & Therapeutics 115 (1), 135-138, 2024 | | 2024 |
| Measuring Tumour Imatinib Concentrations in Gastrointestinal Stromal Tumours: Relevant or Redundant? EL Giraud, LAW de Jong, E van den Hombergh, SEJ Kaal, NP van Erp, ... Cancers 15 (11), 2875, 2023 | | 2023 |
| High-dose short-exposure of osimertinib robustly inhibits growth of patient-derived metastatic colorectal cancer organoids KK Iyer, D Poel, A Miggelenbrink, W Kerkhof, E van den Hombergh, ... Cancer Research 83 (7_Supplement), 4028-4028, 2023 | | 2023 |
| Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer LAW de Jong, M Lambert, NP van Erp, L de Vries, E Chatelut, ... Cancer Chemotherapy and Pharmacology 91 (3), 247-256, 2023 | | 2023 |
| Exposure-response relation in metastatic colorectal cancer organoids after high-dose short-term tyrosine kinase inhibitor exposure K Iyer, A Miggelenbrink, D Poel, E van den Hombergh, L de Jong, ... European Journal of Cancer 174, S22, 2022 | | 2022 |
| Correction to: Wide variation in tissue, systemic, and drain fluid exposure after oxaliplatin‑based HIPEC: results of the GUTOX study LAW de Jong, FMK Elekonawo, M Lambert, JM de Gooyer, HMW Verheul, ... Cancer Chemotherapy and Pharmacology 90 (2), 189-190, 2022 | | 2022 |
| Comments on “Systemic exposure of oxaliplatin and docetaxel in gastric patients with peritonitis carcinomatosis treated with intraperitoneal hyperthermic chemotherapy” LAW de Jong, NP van Erp, PR de Reuver European Journal of Surgical Oncology 47 (5), 1216-1217, 2021 | | 2021 |
| Reply to ‘Hyperthermic intraperitoneal chemotherapy with oxaliplatin—Still not standard of care for patients with colorectal peritoneal metastases’ by Julianov and Saroglu LAW de Jong, NP van Erp British Journal of Clinical Pharmacology 85 (8), 1848, 2019 | | 2019 |
